Monday, February 10, 2025

IMMvention Therapeutix Partners with Novo Nordisk to Forge Oral Treatments for Sickle Cell Disease

Similar articles

In a significant advancement for chronic disease treatment, IMMvention Therapeutix has joined forces with global pharmaceutical leader Novo Nordisk. This strategic collaboration aims to develop innovative oral therapies targeting sickle cell disease (SCD) and other persistent health conditions.

DURHAM, N.C., Jan. 22, 2025 – IMMvention Therapeutix, an emerging biotechnology firm dedicated to the discovery and development of human therapeutics, announced today a pivotal partnership with Novo Nordisk A/S. The alliance focuses on co-developing oral medications utilizing IMMvention’s proprietary small-molecule BACH1 inhibitors, which play a crucial role in regulating cellular responses, oxidative stress, and inflammation across various disease states.

Subscribe Weekly Market Access News

* indicates required

Advancing BACH1 Inhibitors for Sickle Cell Disease

The collaboration leverages IMMvention’s preclinical BACH1 inhibitors, designed to elevate fetal hemoglobin levels, potentially mitigating the pathological effects of SCD. By targeting BACH1, these inhibitors aim to reduce oxidative stress and inflammation, offering a novel therapeutic approach for patients suffering from SCD-related complications.

Exclusive Licensing and Development Pathway

Under the agreement, Novo Nordisk secures an exclusive global license to IMMvention’s BACH1 program. The partnership entails joint efforts to advance the inhibitors through development candidate nomination, after which Novo Nordisk will assume responsibility for further development, regulatory submissions, and worldwide commercialization. This transition ensures that the therapies reach the market efficiently, benefiting a broader patient population.

  • Enhanced therapeutic options for SCD patients through oral medication.
  • Leveraging Novo Nordisk’s global reach accelerates therapy accessibility.
  • Potential expansion of BACH1 inhibitor applications beyond SCD.

IMMvention’s retention of rights to develop brain-penetrant BACH1 inhibitors opens avenues for addressing neurological disorders such as Parkinson’s and Alzheimer’s diseases. This dual-focus strategy underscores the company’s commitment to tackling diverse medical challenges by harnessing the regulatory potential of BACH1.

The partnership with Novo Nordisk marks a milestone for IMMvention Therapeutix, reinforcing its mission to address unmet medical needs with innovative, globally accessible treatments. As both companies pool their expertise, the collaboration promises to deliver impactful therapies that can significantly improve the quality of life for individuals battling chronic and life-threatening diseases.

Source


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article